Verona Pharma submits a new drug application to the US FDA for ensiphentrin for the maintenance treatment of COPD

Verona Farmaceutica srl

Verona Farmaceutica srl LONDON & RALEIGH, NC, June 27, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company) announces the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the approval of ensifentrin for the maintenance treatment of patients with chronic obstructive pulmonary … Read more